---
title: 'Industry Daily Summary: What Happened on October 25, 2026'
headline: GlobalData analysts project $540 million in Mo-Rez sales by 2032
description: The forecast covers annual global sales of GSK’s ovarian cancer drug.
url: https://thebench.bio/news/industry/2026-10-25
topic: industry
date: '2026-10-25'
covers:
- '2026-10-25'
date_published: '2026-10-26T00:03:03Z'
date_modified: '2026-10-26T00:03:03Z'
tags:
- Industry
sources: 1
publisher: TheBench.Bio
---

# Industry Daily Summary: What Happened on October 25, 2026

**GlobalData analysts project $540 million in Mo-Rez sales by 2032**

The forecast covers annual global sales of GSK’s ovarian cancer drug.

## Today in brief

GlobalData’s consensus puts GSK’s Mo-Rez at $540 million in annual global sales in 2032. [1]

## The day in numbers

- **$540 million**: Projected annual global sales for Mo-Rez by 2032, according to GlobalData’s analyst consensus. [1]

## Sources

1. [ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer](<https://www.pharmaceutical-technology.com/analyst-comment/esmo26-gsks-mo-rez-seeks-an-edge-in-a-crowded-adc-field-in-ovarian-cancer/>), Pharmaceutical Technology, 2026-10-25

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmaceutical-technology.com/analyst-comment/esmo26-gsks-mo-rez-seeks-an-edge-in-a-crowded-adc-field-in-ovarian-cancer/>